- Home
- RARE vs MGEE Comparison
RARE vs MGEE Comparison
Compare RARE & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | MGEE |
|---|---|---|
| Founded | 2010 | 1855 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | MGEE |
|---|---|---|
| Price | $34.13 | $78.27 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 15 | 2 |
| Target Price | ★ $85.20 | $79.00 |
| AVG Volume (30 Days) | ★ 1.6M | 155.9K |
| Earning Date | 02-12-2026 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | N/A | ★ 12.85 |
| EPS | N/A | ★ 3.69 |
| Revenue | $630,598,000.00 | ★ $708,516,000.00 |
| Revenue This Year | $19.09 | $10.69 |
| Revenue Next Year | $20.62 | $3.32 |
| P/E Ratio | ★ N/A | $21.23 |
| Revenue Growth | ★ 20.63 | 8.39 |
| 52 Week Low | $25.81 | $77.46 |
| 52 Week High | $46.50 | $96.25 |
Technical Indicators
Market Signals| Indicator | RARE | MGEE |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 39.23 |
| Support Level | $32.64 | $79.87 |
| Resistance Level | $35.12 | $81.62 |
| Average True Range (ATR) | 1.44 | 1.44 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 22.07 | 14.46 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.